Imugene Accounts Payable vs Short Term Debt Analysis

IMU Stock   0.04  0  5.56%   
Imugene financial indicator trend analysis is infinitely more than just investigating Imugene recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Imugene is a good investment. Please check the relationship between Imugene Accounts Payable and its Short Term Debt accounts. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Imugene. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

Accounts Payable vs Short Term Debt

Accounts Payable vs Short Term Debt Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Imugene Accounts Payable account and Short Term Debt. At this time, the significance of the direction appears to have almost identical trend.
Accounts PayableShort Term DebtDiversified AwayAccounts PayableShort Term DebtDiversified Away100%
The correlation between Imugene's Accounts Payable and Short Term Debt is 0.92. Overlapping area represents the amount of variation of Accounts Payable that can explain the historical movement of Short Term Debt in the same time period over historical financial statements of Imugene, assuming nothing else is changed. The correlation between historical values of Imugene's Accounts Payable and Short Term Debt is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Accounts Payable of Imugene are associated (or correlated) with its Short Term Debt. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Short Term Debt has no effect on the direction of Accounts Payable i.e., Imugene's Accounts Payable and Short Term Debt go up and down completely randomly.

Correlation Coefficient

0.92
Relationship DirectionPositive 
Relationship StrengthVery Strong

Accounts Payable

An accounting item on the balance sheet that represents Imugene obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of Imugene are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. The amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities.

Short Term Debt

Most indicators from Imugene's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Imugene current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Imugene. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
Selling General Administrative is likely to gain to about 47.3 M in 2024. Issuance Of Capital Stock is likely to gain to about 57.5 M in 2024
 2021 2022 2023 2024 (projected)
Reconciled Depreciation203.4K190.3K3.3M3.5M
Net Interest Income71.9K1.9M4.0M4.2M

Imugene fundamental ratios Correlations

0.040.670.720.990.850.96-0.98-0.840.850.990.890.640.990.970.890.930.69-0.970.730.840.990.710.880.96-0.76
0.040.490.47-0.040.360.13-0.02-0.410.370.04-0.11-0.390.050.11-0.010.120.27-0.160.450.370.070.46-0.150.260.13
0.670.490.990.570.950.82-0.56-0.960.890.590.70.460.60.730.680.740.9-0.720.990.950.641.00.650.85-0.44
0.720.470.990.630.970.86-0.62-0.980.930.650.740.490.660.780.720.790.9-0.771.00.970.691.00.690.89-0.49
0.99-0.040.570.630.780.93-0.99-0.770.790.990.870.630.990.950.860.90.61-0.950.640.770.990.620.860.91-0.77
0.850.360.950.970.780.94-0.76-0.980.970.780.830.570.790.90.810.880.87-0.860.971.00.820.960.790.95-0.61
0.960.130.820.860.930.94-0.91-0.930.910.930.90.70.930.960.860.910.79-0.950.860.940.950.850.880.98-0.67
-0.98-0.02-0.56-0.62-0.99-0.76-0.910.76-0.77-1.0-0.8-0.59-1.0-0.93-0.8-0.86-0.550.96-0.62-0.75-0.99-0.61-0.79-0.910.71
-0.84-0.41-0.96-0.98-0.77-0.98-0.930.76-0.94-0.79-0.8-0.52-0.79-0.87-0.8-0.87-0.880.87-0.98-0.98-0.82-0.97-0.76-0.960.58
0.850.370.890.930.790.970.91-0.77-0.940.80.80.530.80.910.80.870.82-0.880.930.970.830.920.760.94-0.63
0.990.040.590.650.990.780.93-1.0-0.790.80.810.591.00.940.810.870.57-0.970.650.781.00.640.80.92-0.71
0.89-0.110.70.740.870.830.9-0.8-0.80.80.810.690.810.910.970.930.85-0.810.760.820.830.711.00.87-0.82
0.64-0.390.460.490.630.570.7-0.59-0.520.530.590.690.60.610.570.50.47-0.610.490.570.60.490.680.59-0.41
0.990.050.60.660.990.790.93-1.0-0.790.81.00.810.60.940.810.870.58-0.970.660.781.00.650.80.93-0.71
0.970.110.730.780.950.90.96-0.93-0.870.910.940.910.610.940.920.960.74-0.930.790.890.960.770.890.96-0.81
0.89-0.010.680.720.860.810.86-0.8-0.80.80.810.970.570.810.920.970.85-0.790.740.80.830.690.970.87-0.92
0.930.120.740.790.90.880.91-0.86-0.870.870.870.930.50.870.960.970.83-0.860.80.860.890.760.920.93-0.89
0.690.270.90.90.610.870.79-0.55-0.880.820.570.850.470.580.740.850.83-0.670.920.870.620.880.830.81-0.64
-0.97-0.16-0.72-0.77-0.95-0.86-0.950.960.87-0.88-0.97-0.81-0.61-0.97-0.93-0.79-0.86-0.67-0.77-0.86-0.97-0.76-0.79-0.960.63
0.730.450.991.00.640.970.86-0.62-0.980.930.650.760.490.660.790.740.80.92-0.770.970.690.990.710.89-0.51
0.840.370.950.970.771.00.94-0.75-0.980.970.780.820.570.780.890.80.860.87-0.860.970.810.970.780.95-0.59
0.990.070.640.690.990.820.95-0.99-0.820.831.00.830.61.00.960.830.890.62-0.970.690.810.680.820.95-0.72
0.710.461.01.00.620.960.85-0.61-0.970.920.640.710.490.650.770.690.760.88-0.760.990.970.680.660.88-0.46
0.88-0.150.650.690.860.790.88-0.79-0.760.760.81.00.680.80.890.970.920.83-0.790.710.780.820.660.84-0.84
0.960.260.850.890.910.950.98-0.91-0.960.940.920.870.590.930.960.870.930.81-0.960.890.950.950.880.84-0.69
-0.760.13-0.44-0.49-0.77-0.61-0.670.710.58-0.63-0.71-0.82-0.41-0.71-0.81-0.92-0.89-0.640.63-0.51-0.59-0.72-0.46-0.84-0.69
Click cells to compare fundamentals

Imugene Account Relationship Matchups

Imugene fundamental ratios Accounts

201920202021202220232024 (projected)
Total Assets65.2M71.8M147.6M197.1M151.4M159.0M
Short Long Term Debt Total69.3K271.0K673.4K553.5K1.5M1.6M
Other Current Liab1.8M3.6M2.7M3.6M22.4M23.5M
Total Current Liabilities2.9M4.5M7.4M6.1M29.3M30.8M
Total Stockholder Equity59.8M65.0M138.7M189.6M118.3M124.2M
Property Plant And Equipment Net155.6K466.0K862.8K683.0K1.7M1.8M
Current Deferred Revenue390.6K738.3K1.3M1.6M1.9M2.0M
Net Debt(30.0M)(29.2M)(99.2M)(152.6M)(91.6M)(87.0M)
Retained Earnings(47.3M)(65.7M)(103.5M)(141.4M)(289.8M)(275.3M)
Accounts Payable1.0M759.7K4.5M2.3M6.0M6.3M
Cash30.1M29.5M99.9M153.2M93.1M97.8M
Non Current Assets Total30.7M35.5M33.8M31.4M38.4M40.3M
Cash And Short Term Investments30.1M29.5M99.9M153.2M94.5M99.3M
Net Receivables4.2M6.7M12.8M12.1M12.6M13.2M
Common Stock Shares Outstanding4.1B4.7B5.6B6.3B7.1B7.4B
Liabilities And Stockholders Equity65.2M71.8M147.6M197.1M151.4M159.0M
Non Current Liabilities Total2.5M2.3M1.5M1.4M3.8M4.0M
Other Stockholder Equity(45.5M)(1.0)(127.3M)(173.0M)(155.7M)(147.9M)
Total Liab5.4M6.8M8.9M7.4M33.1M34.8M
Property Plant And Equipment Gross155.6K718.9K1.3M1.0M2.6M2.8M
Total Current Assets34.5M36.3M113.8M165.7M113.0M118.7M
Accumulated Other Comprehensive Income14.3M17.6M11.4M16.7M37.8M39.7M
Short Term Debt60.9K106.0K184.2K191.1K912.5K958.1K
Intangible Assets30.5M34.9M32.7M30.5M34.1M35.8M
Common Stock92.8M113.1M230.8M314.4M370.3M388.8M
Other Liab2.5M2.2M987.1K990.6K1.1M1.1M
Net Tangible Assets29.3M30.1M106.0M159.1M183.0M192.2M
Long Term Investments80.6K115.2K252.4K217.6K2.4M2.5M
Property Plant Equipment155.6K466.0K862.8K683.0K614.7K645.4K
Other Current Assets194.1K170.1K1.1M401.6K5.9M6.2M
Long Term Debt Total8.4K165.0K489.3K362.4K326.2K462.4K
Net Invested Capital59.8M65.0M138.7M188.4M118.3M85.8M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Imugene Stock Analysis

When running Imugene's price analysis, check to measure Imugene's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Imugene is operating at the current time. Most of Imugene's value examination focuses on studying past and present price action to predict the probability of Imugene's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Imugene's price. Additionally, you may evaluate how the addition of Imugene to your portfolios can decrease your overall portfolio volatility.